The European Medicines Agency has today adopted a positive scientific opinion for the world’s first malaria vaccine, submitted for approval by vaccine manufacturer GSK. The vaccine was developed in partnership with the PATH Malaria Vaccine Initiative, and is the first candidate vaccine for the prevention of malaria to reach this milestone. The vaccine has been designed to prevent malaria caused by the most prevalent parasite in sub-Saharan Africa. Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected mosquitoes. In 2013, malaria caused an estimated 584 000 deaths, mostly among African children.
For more information, please visit the following: